Home > Journals > Minerva Ortopedica e Traumatologica > Past Issues > Minerva Ortopedica e Traumatologica 2020 December;71(4) > Minerva Ortopedica e Traumatologica 2020 December;71(4):151-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Ortopedica e Traumatologica 2020 December;71(4):151-9

DOI: 10.23736/S0394-3410.20.04012-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

New opportunities for the management of gonarthrosis: an observational study

Giovanni B. VAVALLE, Francesco FORTUNATO

Unit of Orthopedics, Santa Maria GVM Care and Research Hospital, Bari, Italy



BACKGROUND: Gonarthrosis, a common form of degenerative osteoarthritis (OA), is characterized by inflammation, pain and limitation of movement. Currently, nonsteroidal anti-inflammatory drugs, analgesics and steroids are the only symptom-modifying agents approved as OA interventions, but their consistent side effects limit their use. Recently, clinical trials have been performed to evaluate whether some dietary supplements can be used for a long-term period without side effects. This work presents an observational study comparing the dietary supplement Flexart® Flogo and a glucosamine sulphate therapy for the treatment of OA, with the aim to verify whether Flexart® Flogo could be considered a promising therapeutic option.
METHODS: Patients between 50 and 70 years old with a diagnosis of stage I or II gonarthrosis were included in the study and evaluated for 90 days, for both treatments. A Visual Analogue Scale (VAS) was used for a subjective unidimensional measure of pain intensity. The joint functionality has been evaluated with the Western Ontario and McMaster Universities Arthritis Index (WOMAC).
RESULTS: The use of Flexart® Flogo was associated with a significant reduction of VAS-reported pain score and an improvement in physical function, and overall symptomatology at each follow-up, compared to treatment with glucosamine sulphate. In particular, the improvement of joint functionality has been observed in patients with severe pain at baseline.
CONCLUSIONS: The treatment with Flexart® Flogo promotes the relief from OA symptoms, avoiding adverse effects of conventional pharmacological treatments. Consequently, it can be considered a safe and effective treatment for OA patients.


KEY WORDS: Osteoarthritis; Dietary supplements; Visual Analog Scale

top of page